| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = $2,143,077 ) |
| | 2023 | 2023 | KINOXIS THERAPEUTICS PTY LTD | SUITE 201 697 BURKE ROAD | CAMBERWELL | VICTORIA | | | AUS | UH3DA048743 | Advancing KNX100 for the treatment of opioid withdrawal: preclinical efficacy and toxicology, and a phase 1 clinical program. | 000 | 2 | NIH | 6/1/2023 | $2,149,117 |
| | 2023 | 2019 | KINOXIS THERAPEUTICS PTY LTD | SUITE 201 697 BURKE ROAD | CAMBERWELL | VICTORIA | | | AUS | UG3DA048743 | Advancing KNX100 for the treatment of opioid withdrawal: preclinical efficacy and toxicology, and a phase 1 clinical program. | 000 | 1 | NIH | 5/15/2023 | -$6,040 |
|
| Issue Date FY: 2021 ( Subtotal = $0 ) |
| | 2021 | 2019 | KINOXIS THERAPEUTICS PTY LTD | SUITE 201 | CAMBERWELL | VIC | | | AUS | UG3DA048743 | Advancing KNX100 for the treatment of opioid withdrawal: preclinical efficacy and toxicology, and a phase 1 clinical program. | 001 | 1 | NIH | 6/24/2021 | $0 |
| | 2021 | 2019 | KINOXIS THERAPEUTICS PTY LTD | SUITE 201 | CAMBERWELL | VIC | | | AUS | UG3DA048743 | Advancing KNX100 for the treatment of opioid withdrawal: preclinical efficacy and toxicology, and a phase 1 clinical program. | 000 | 1 | NIH | 10/20/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $2,798,940 ) |
| | 2019 | 2019 | KINOXIS THERAPEUTICS PTY LTD | SUITE 201, 697 BURKE RD | CAMBERWELL | VIC | 3124 | | AUS | UG3DA048743 | Advancing KNX100 for the treatment of opioid withdrawal: preclinical efficacy and toxicology, and a phase 1 clinical program. | 000 | 1 | NIH | 9/20/2019 | $2,798,940 |
|
|
